Aurora Barberá

Dr. Aurora Barberá

Barcelona Institute for Global Health, Barcelona, Catalonia, Spain
orcid
Postdoctoral researcher at Barcelona Institute for Global He...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MBMiren Bravo
Miren Bravo
IRImma Raurell
Imma Raurell
DHDiana Hide
Diana Hide
AFAnabel Fernández-Iglesias
Anabel Fernández-Iglesias
MGMar Gil
Mar Gil
Maria MartellMaria Martell
Maria Martell
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function improving early NASH stages. Sprague-Dawley rats were fed with high fat glucose-fructose diet (HFGFD), or control diet (CD) for 8 weeks and then treated with simvastatin (sim) (10 mg·kg−1·day−1), atorvastatin (ato) (10 mg·kg−1·day−1) or vehicle during 2 weeks. Biochemical, histological and hemodynamic determinations were carried out. Sinusoidal endothelial dysfunction was assessed in individualized sorted LSEC and hepatic stellate cells (HSC) from animal groups and in whole liver samples. HFGFD rats showed full NASH features without fibrosis but with significantly increased portal pressure compared with CD rats (10.47 ± 0.37 mmHg vs 8.30 ± 0.22 mmHg; p < 0.001). Moreover, HFGFD rats showed a higher percentage of capillarized (CD32b−/CD11b−) LSEC (8% vs 1%, p = 0.005) showing a contractile phenotype associated to HSC activation. Statin treatments caused a significant portal pressure reduction (sim: 9.29 ± 0.25 mmHg, p < 0.01; ato: 8.85 ± 0.30 mmHg, p < 0.001), NASH histology reversion, along with significant recovery of LSEC differentiation and a regression of HSC activation to a more quiescent phenotype. In an early NASH model without fibrosis with PH, LSEC transition to capillarization and HSC activation are reverted by statin treatment inducing portal pressure decrease and NASH features improvement.

1 May 2021 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
MBMiren Bravo
Miren Bravo
IRImma Raurell
Imma Raurell
Aurora BarberáAurora Barberá
Aurora Barberá
DHDiana Hide
Diana Hide
MGMar Gil
Mar Gil
Maria MartellMaria Martell
Maria Martell
In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients.

1 October 2020 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
DHDiana Hide
Diana Hide
MGMar Gil
Mar Gil
FAFernanda da Silva Andrade
Fernanda da Silva Andrade
Diana RafaelDiana Rafael
Diana Rafael
ISImmaculada Raurell Saborit
Immaculada Raurell Saborit
Maria MartellMaria Martell
Maria Martell

8 August 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
Aurora BarberáAurora Barberá
Aurora Barberá
IRImma Raurell
Imma Raurell
TGTeresa García‐Lezana
Teresa García‐Lezana
MTManuel Torres‐Arauz
Manuel Torres‐Arauz
MBMiren Bravo
Miren Bravo
SASalvador Augustin
Salvador Augustin

20 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
IPIris Pinheiro
Iris Pinheiro
Aurora BarberáAurora Barberá
Aurora Barberá
ISImmaculada Raurell Saborit
Immaculada Raurell Saborit
FEFederico Estrella
Federico Estrella
MLMarcel de Leeuw
Marcel de Leeuw
SASalvador Augustin
Salvador Augustin
The gut microbiome has a recognized role in Non-alcoholic fatty liver disease (NAFLD) and associated comorbidities such as Type-2 diabetes and obesity. Stool transplantation has been shown to improve disease by restoring endothelial function and insulin signaling. However, more patient-friendly treatments are required. The present study aimed to test the effect of a defined bacterial consortium of nine gut commensal strains in two in vivo rodent models of Non-alcoholic steatohepatitis (NASH): a rat model of NASH and portal hypertension (PHT), and the Stelic animal (mouse) model (STAM™). In both studies the consortium was administered orally q.d. after disease induction. In the NASH rats, the consortium was administered for 2 weeks and compared to stool transplant. In the STAM™ study administration was performed for 4 weeks, and the effects compared to vehicle or Telmisartan at the stage of NASH/early fibrosis. A second group of animals was followed for another 3 weeks to assess later-stage fibrosis. In the NASH rats, an improvement in PHT and endothelial function was observed. Gut microbial compositional changes also revealed that the consortium achieved a more defined and richer replacement of the gut microbiome than stool transplantation. Moreover, liver transcriptomics suggested a beneficial modulation of pro-fibrogenic pathways. An improvement in liver fibrosis was then confirmed in the STAM™ study. In this study, the bacterial consortium improved the NAFLD activity score, consistent with a decrease in steatosis and ballooning. Serum cytokeratin-18 levels were also reduced. Therefore, administration of a specific bacterial consortium of defined composition can ameliorate NASH, PHT, and fibrosis, and delay disease progression.

29 October 2022 in JHEP Reports
Verified
Journal Article
Open access
JRJesús Rivera-Esteban
Jesús Rivera-Esteban
Aurora BarberáAurora Barberá
Aurora Barberá
MSMaria Teresa Salcedo
Maria Teresa Salcedo
MMMaria Martell
Maria Martell
JGJoan Genescà
Joan Genescà
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs